-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RXG9mE8KEO8cG7C+qp39/k5Y6vMLt06EMb0NSq5wfOlKvAKRKDirhJUBU/7lYAQP wDR6NVcvbhHu1zMdJh3vDQ== 0000898432-09-000093.txt : 20090127 0000898432-09-000093.hdr.sgml : 20090127 20090127190930 ACCESSION NUMBER: 0000898432-09-000093 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090123 FILED AS OF DATE: 20090127 DATE AS OF CHANGE: 20090127 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10275 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121-1117 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 10275 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121-1117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BVF INVESTMENTS LLC CENTRAL INDEX KEY: 0001132245 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 09549386 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST. 39TH FL CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: C/O GROSVENOR CAPITAL MANAGEMENT LP STREET 2: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 09549388 BUSINESS ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BVF PARTNERS L P/IL CENTRAL INDEX KEY: 0001055947 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 09549389 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST STREET 2: 39TH FL CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE STREET 2: SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BVF INC/IL CENTRAL INDEX KEY: 0001056807 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 09549390 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST STREET 2: 39TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: C/O GROSVENOR CAPITAL MANAGEMENT STREET 2: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND II LP CENTRAL INDEX KEY: 0001102444 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 09549387 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST STREET 2: 39TH FL. CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: C/O GROSVENOR CAPITAL MANAGEMENT STREET 2: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 4 1 bvf-ligand_form4ex.xml X0303 4 2009-01-23 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001055947 BVF PARTNERS L P/IL 900 N. MICHIGAN AVENUE SUITE 1100 CHICAGO IL 60611 0 0 1 1 Indirect Beneficial Owner 0000918923 BIOTECHNOLOGY VALUE FUND L P 900 N. MICHIGAN AVENUE, SUITE 1100 CHICAGO IL 60611 0 0 1 1 Indirect Beneficial Owner 0001102444 BIOTECHNOLOGY VALUE FUND II LP C/O GROSVENOR CAPITAL MANAGEMENT 900 N. MICHIGAN AVENUE, SUITE 1100 CHICAGO IL 60611 0 0 1 1 Indirect Beneficial Owner 0001132245 BVF INVESTMENTS LLC C/O GROSVENOR CAPITAL MANAGEMENT LP 900 N. MICHIGAN AVENUE, SUITE 1100 CHICAGO IL 60611 0 0 1 1 Indirect Beneficial Owner 0001056807 BVF INC/IL C/O GROSVENOR CAPITAL MANAGEMENT 900 N. MICHIGAN AVENUE, SUITE 1100 CHICAGO IL 60611 0 0 1 1 Indirect Beneficial Owner Common Stock 2009-01-23 4 P 0 9728 2.0000 A 15972207 I See Footnotes Common Stock 2009-01-23 4 P 0 6000 2.0000 A 15978207 I See footnotes Common Stock 2009-01-23 4 P 0 24000 2.0000 A 16002207 I See footnotes Common Stock 2009-01-26 4 P 0 1008 2.0000 A 16003215 I See footnotes Common Stock 2009-01-26 4 P 0 1000 2.0000 A 16004215 I See footnotes Common Stock 2009-01-26 4 P 0 2000 2.0000 A 16006215 I See footnotes Warrant 8.59 2008-12-23 4 J 0 31200 8.59 A 2008-12-23 2011-04-19 Common Stock 31200 31200 I See footnotes Warrant 8.59 2008-12-23 4 J 0 21500 8.59 A 2008-12-23 2011-04-19 Common Stock 21500 21500 I See footnotes Warrant 8.59 2008-12-23 4 J 0 83000 8.59 A 2008-12-23 2011-04-19 Common Stock 83000 83000 I See footnotes The shares and underlying warrants reported in this response are indirectly beneficially owned by BVF Partners, L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 4, and by its general partner, BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") and Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P."), both investment limited partnerships. Partners also is the manager of BVF Investments, L.L.C., a Delaware limited liability company ("Investments"). Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Samana Capital, L.P., the majority member of Investments, in the shares of Common Stock reported in Table I as being beneficially owned by Investments. Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. This joint filing on Form 4 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing. Shares and underlying warrants directly beneficially owned by BVF, L.P. Shares and underlying warrants directly beneficially owned by BVF2, L.P. Shares and underlying warrants directly owned by Investments Total amount of shares and underlying warrants indirectly beneficially owned by Partners and BVF Inc. Shares and underlying warrants issued in exchange of shares and underlying warrants of Pharmacopeia, Inc. in connection with its merger with Ligand Pharmaceuticals Incorporated. BVF PARTNERS L.P., By: BVF Inc., its General Partner, By: /s/ Mark N. Lampert, President 2009-01-27 BIOTECHNOLOGY VALUE FUND, L.P., By: BVF Partners L.P., its General Partner, By: BVF Inc., its General Partner, By: /s/ Mark N. Lampert, President 2009-01-27 BIOTECHNOLOGY VALUE FUND II, L.P., By: BVF Partners L.P., its General Partner, By: BVF Inc., its General Partner, By: /s/ Mark N. Lampert, President 2009-01-27 BVF INVESTMENTS, L.L.C., By: BVF Partners, L.P., its Manager, By: BVF Inc., its General Partner, By: /s/ 2009-01-27 BVF INC., By: /s/ Mark N. Lampert, President 2009-01-27 -----END PRIVACY-ENHANCED MESSAGE-----